Viventia initiates patient treatment in bladder cancer trial
Viventia's lead product, Proxinium, is being developed to treat late stage, locally advanced head and neck cancer and is currently enrolling patients in a phase III global trial
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.